A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States

Abstract Background The National Comprehensive Cancer Network recommends that patients with hormone receptor-positive early breast cancer be considered for adjuvant endocrine therapy (ET) after primary treatment like surgical excision. Adjuvant chemotherapy (CT) use primarily depends on risk of recu...

Full description

Bibliographic Details
Main Authors: Jacqueline Brown, Savannah Scardo, Michael Method, Dan Schlauch, Amanda Misch, Shaita Picard, Erika Hamilton, Suzanne Jones, Howard Burris, David Spigel
Format: Article
Language:English
Published: BMC 2022-05-01
Series:BMC Cancer
Subjects:
Breast neoplasm
Early breast cancer
Diagnostic test
HR+ breast cancer
Ki-67
Ki-67 index
Online Access:https://doi.org/10.1186/s12885-022-09557-6

Internet

https://doi.org/10.1186/s12885-022-09557-6

Similar Items